{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:28:33Z","timestamp":1791332913570,"version":"4.3.1"},"reference-count":66,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,9,8]],"date-time":"2009-09-08T00:00:00Z","timestamp":1252368000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2010,1]]},"abstract":"<jats:p>Adult T\u2010cell leukemia (ATL) is an aggressive malignancy of activated CD4<jats:sup>+<\/jats:sup> T cells associated with human T\u2010cell leukemia virus type I (HTLV\u2010I) infection. No conventional chemotherapy regimen has appeared successful in patients with ATL, thus establishing effective therapy is urgently required. In some cases, ATL tumor cells express CD30 on the cell surface, therefore, a therapy with mAb against CD30 would be beneficial. To investigate the effect of CD30\u2010mediated therapy on ATL, we assessed SGN\u201030, a chimeric anti\u2010CD30 mAb, and SGN\u201035, a monomethyl auristatin E\u2010conjugated anti\u2010CD30 mAb, <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>. Three HTLV\u2010I\u2010infected cell lines were co\u2010cultured with SGN\u201030 or SGN\u201035, and the growth\u2010inhibitory effects on the HTLV\u2010I\u2010infected cells were evaluated using an <jats:italic>in vitro<\/jats:italic> cell proliferation assay and cell cycle analysis. SGN\u201030 and SGN\u201035 showed growth\u2010inhibitory activity against the HTLV\u2010I\u2010infected cell lines by apoptosis and\/or cell growth arrest <jats:italic>in vitro<\/jats:italic>. To further investigate the effects of SGN\u201030 and SGN\u201035 on HTLV\u2010I\u2010infected cells <jats:italic>in vivo<\/jats:italic>, we used NOD\/SCID mice subcutaneously engrafted with HTLV\u2010I\u2010infected cells. Both mAbs significantly inhibited the growth of HTLV\u2010I\u2010infected cell tumors in the NOD\/SCID murine xenograft models. These data suggest that CD30\u2010mediated therapy with SGN\u201030 or SGN\u201035 would be useful for patients with ATL. (<jats:italic>Cancer Sci<\/jats:italic> 2009)<\/jats:p>","DOI":"10.1111\/j.1349-7006.2009.01354.x","type":"journal-article","created":{"date-parts":[[2009,9,8]],"date-time":"2009-09-08T15:08:51Z","timestamp":1252422531000},"page":"224-230","source":"Crossref","is-referenced-by-count":22,"title":["Susceptibility of human T\u2010cell leukemia virus type I\u2010infected cells to humanized anti\u2010CD30 monoclonal antibodies <i>in vitro<\/i> and <i>in vivo<\/i>"],"prefix":"10.1111","volume":"101","author":[{"given":"Naoyoshi","family":"Maeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Muta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezogelin","family":"Oflazoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunobu","family":"Yoshikai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,12,9]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2111"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3601"},{"key":"e_1_2_7_4_2","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1182\/blood.V72.5.1805.1805","article-title":"Therapy of patients with human T\u2010cell lymphotrophic virus I\u2010induced adult T\u2010cell leukemia with anti\u2010Tac, a monoclonal antibody to the receptor for interleukin\u20102","volume":"72","author":"Waldmann TA","year":"1988","journal-title":"Blood"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.6.1701.1701"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.11.4063.bloodjournal86114063"},{"key":"e_1_2_7_7_2","first-page":"6977","article-title":"IL\u20102Ralpha\u2010Directed monoclonal antibodies provide effective therapy in a murine model of adult T\u2010cell leukemia by a mechanism other than blockade of IL\u20102\/IL\u20102Ralpha interaction","volume":"60","author":"Phillips KE","year":"2000","journal-title":"Cancer Res"},{"key":"e_1_2_7_8_2","first-page":"1083","article-title":"Proteasome inhibitor PS\u2010341, a potential therapeutic agent for adult T\u2010cell leukemia","volume":"62","author":"Tan C","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0107"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1088"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-05-1709"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4757"},{"key":"e_1_2_7_13_2","first-page":"6453","article-title":"Effective therapy for a murine model of adult T\u2010cell leukemia with the humanized anti\u2010CD52 monoclonal antibody, Campath\u20101H","volume":"63","author":"Zhang Z","year":"2003","journal-title":"Cancer Res"},{"key":"e_1_2_7_14_2","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.4049\/jimmunol.151.2.1075","article-title":"Humanized Mik\u03b21, a humanized antibody to the IL\u20102 receptor \u03b2\u2010chain that acts synergistically with humanized anti\u2010TAC","volume":"151","author":"Hakimi J","year":"1993","journal-title":"J Immunol"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0983"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199409049728"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.1995.tb00272.x"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.38.824"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10190"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-2-29"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2005.00106.x"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1080\/02841860802657235"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.23.021704.115839"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2291"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M608817200"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.13.4307"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0515"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4607"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0702496104"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.8972"},{"key":"e_1_2_7_31_2","doi-asserted-by":"crossref","first-page":"5896","DOI":"10.4049\/jimmunol.151.11.5896","article-title":"Functional effects of CD30 on a large granular lymphoma cell line, YT. Inhibition of cytotoxicity, regulation of CD28 and IL\u20102R, and induction of homotypic aggregation","volume":"151","author":"Bowen MA","year":"1993","journal-title":"J Immunol"},{"key":"e_1_2_7_32_2","first-page":"3736","article-title":"The anti\u2010CD30 monoclonal antibody SGN\u201030 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin\u2019s disease","volume":"62","author":"Wahl AF","year":"2002","journal-title":"Cancer Res"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403884"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-097014"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-099317"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07740.x"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt832"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0039"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0789"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.843.11.2"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M510026200"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07146.x"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1028"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2883"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.77.12.7415"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1038\/294770a0"},{"key":"e_1_2_7_47_2","doi-asserted-by":"crossref","first-page":"6892","DOI":"10.1128\/jvi.65.12.6892-6899.1991","article-title":"Human T\u2010cell leukemia virus type I Tax induces expression of the Rel\u2010related family of kappa B enhancer\u2010binding proteins: evidence for a pretranslational component of regulation","volume":"65","author":"Arima N","year":"1991","journal-title":"J Virol"},{"key":"e_1_2_7_48_2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1182\/blood.V72.1.234.234","article-title":"A Ki\u20101 (CD30)\u2010positive human cell line (Karpas 299) established from a high\u2010grade non\u2010Hodgkin\u2019s lymphoma, showing a 2;5 translocation and rearrangement of the T\u2010cell receptor \u03b2\u2010chain gene","volume":"72","author":"Fischer P","year":"1988","journal-title":"Blood"},{"key":"e_1_2_7_49_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.78.9.4582-4590.2004"},{"key":"e_1_2_7_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06445.x"},{"key":"e_1_2_7_51_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2008.00917.x"},{"key":"e_1_2_7_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204128"},{"key":"e_1_2_7_53_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1205337"},{"key":"e_1_2_7_54_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208976"},{"key":"e_1_2_7_55_2","first-page":"2360","article-title":"Constitutive activation of NF\u2010\u03baB in primary adult T\u2010cell leukemia cells","volume":"93","author":"Mori N","year":"1999","journal-title":"Blood"},{"key":"e_1_2_7_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2008.04.018"},{"key":"e_1_2_7_57_2","first-page":"3915","article-title":"Constitutive activation of transcription factor AP\u20101 in primary adult T\u2010cell leukemia cells","volume":"95","author":"Mori N","year":"2000","journal-title":"Blood"},{"key":"e_1_2_7_58_2","doi-asserted-by":"publisher","DOI":"10.1089\/08892220050193029"},{"key":"e_1_2_7_59_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0925"},{"key":"e_1_2_7_60_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910450515"},{"key":"e_1_2_7_61_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.20633"},{"key":"e_1_2_7_62_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24012"},{"key":"e_1_2_7_63_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1990.00282.x"},{"key":"e_1_2_7_64_2","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1182\/blood.V77.9.1983.1983","article-title":"Clinical significance of soluble CD30 antigen in the sera of patients with untreated Hodgkin\u2019s disease","volume":"77","author":"Gause A","year":"1991","journal-title":"Blood"},{"key":"e_1_2_7_65_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.6.1355"},{"key":"e_1_2_7_66_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1532"},{"key":"e_1_2_7_67_2","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200201)32:1<163::AID-IMMU163>3.0.CO;2-T"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1349-7006.2009.01354.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1349-7006.2009.01354.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T16:24:40Z","timestamp":1698769480000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1349-7006.2009.01354.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12,9]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["10.1111\/j.1349-7006.2009.01354.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1349-7006.2009.01354.x","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12,9]]}}}